Drug Trial Radar · NCT04056689
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jul 23, 2019
Primary completion
Dec 2, 2020
Study completion Dec 2, 2020
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Aug 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.
Conditions
- Parkinson's Disease
Interventions
DNL151Drug
Oral repeating dose
PlaceboDrug
Oral repeating dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Randomization to Day 42
- Number of Subjects with laboratory test abnormalitiesTime frame: Randomization to Day 42
- Number of Subjects with vital sign abnormalitiesTime frame: Randomization to Day 42
- Number of Subjects with electrocardiogram (ECG) abnormalitiesTime frame: Randomization to Day 42
- Number of Subjects with clinically significant neurological examination abnormalitiesTime frame: Randomization to Day 42
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
PPD Clinical Research Unit
Orlando, Florida
Quest Research Institute
Farmington Hills, Michigan
UZ Leuven
Leuven, Belgium
QPS
Leeuwarden, Netherlands
Centre for Human Drug Research
Leiden, South Holland, Netherlands
Royal Liverpool University Hospital
Liverpool, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.